nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—TAAR1—female reproductive system—urinary bladder cancer	0.0318	0.0662	CbGeAlD
Methamphetamine—SLC18A1—vagina—urinary bladder cancer	0.0305	0.0637	CbGeAlD
Methamphetamine—SLC18A2—prostate gland—urinary bladder cancer	0.0198	0.0412	CbGeAlD
Methamphetamine—SLC18A1—lymph node—urinary bladder cancer	0.0198	0.0412	CbGeAlD
Methamphetamine—CYP2D6—urine—urinary bladder cancer	0.0184	0.0384	CbGeAlD
Methamphetamine—Aspartame—TRPV1—urinary bladder cancer	0.0159	0.388	CrCbGaD
Methamphetamine—SLC22A3—prostate gland—urinary bladder cancer	0.0141	0.0293	CbGeAlD
Methamphetamine—MAOB—prostate gland—urinary bladder cancer	0.013	0.0272	CbGeAlD
Methamphetamine—SLC22A3—seminal vesicle—urinary bladder cancer	0.0119	0.0248	CbGeAlD
Methamphetamine—MAOA—prostate gland—urinary bladder cancer	0.0111	0.0232	CbGeAlD
Methamphetamine—MAOB—seminal vesicle—urinary bladder cancer	0.011	0.023	CbGeAlD
Methamphetamine—SLC18A2—female reproductive system—urinary bladder cancer	0.0108	0.0225	CbGeAlD
Methamphetamine—ADRA2C—prostate gland—urinary bladder cancer	0.0107	0.0223	CbGeAlD
Methamphetamine—SLC22A5—prostate gland—urinary bladder cancer	0.0102	0.0213	CbGeAlD
Methamphetamine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00997	0.0208	CbGeAlD
Methamphetamine—Pseudoephedrine—IL2—urinary bladder cancer	0.00978	0.239	CrCbGaD
Methamphetamine—SLC18A2—vagina—urinary bladder cancer	0.00976	0.0203	CbGeAlD
Methamphetamine—SLC22A3—renal system—urinary bladder cancer	0.0096	0.02	CbGeAlD
Methamphetamine—SLC22A3—urethra—urinary bladder cancer	0.00943	0.0196	CbGeAlD
Methamphetamine—MAOA—seminal vesicle—urinary bladder cancer	0.0094	0.0196	CbGeAlD
Methamphetamine—ADRA2C—seminal vesicle—urinary bladder cancer	0.00904	0.0188	CbGeAlD
Methamphetamine—MAOB—renal system—urinary bladder cancer	0.00888	0.0185	CbGeAlD
Methamphetamine—MAOB—urethra—urinary bladder cancer	0.00872	0.0182	CbGeAlD
Methamphetamine—Benzphetamine—POR—urinary bladder cancer	0.0087	0.213	CrCbGaD
Methamphetamine—SLC22A5—seminal vesicle—urinary bladder cancer	0.00866	0.018	CbGeAlD
Methamphetamine—ADRA2A—prostate gland—urinary bladder cancer	0.00853	0.0178	CbGeAlD
Methamphetamine—SLC22A3—female reproductive system—urinary bladder cancer	0.00769	0.016	CbGeAlD
Methamphetamine—MAOA—renal system—urinary bladder cancer	0.00758	0.0158	CbGeAlD
Methamphetamine—SLC6A4—female reproductive system—urinary bladder cancer	0.00748	0.0156	CbGeAlD
Methamphetamine—MAOA—urethra—urinary bladder cancer	0.00744	0.0155	CbGeAlD
Methamphetamine—ADRA2C—renal system—urinary bladder cancer	0.00728	0.0152	CbGeAlD
Methamphetamine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00721	0.015	CbGeAlD
Methamphetamine—ADRA2C—urethra—urinary bladder cancer	0.00716	0.0149	CbGeAlD
Methamphetamine—MAOB—female reproductive system—urinary bladder cancer	0.00711	0.0148	CbGeAlD
Methamphetamine—SLC22A5—renal system—urinary bladder cancer	0.00698	0.0145	CbGeAlD
Methamphetamine—SLC22A3—vagina—urinary bladder cancer	0.00695	0.0145	CbGeAlD
Methamphetamine—SLC22A5—urethra—urinary bladder cancer	0.00685	0.0143	CbGeAlD
Methamphetamine—SLC6A2—female reproductive system—urinary bladder cancer	0.00659	0.0137	CbGeAlD
Methamphetamine—MAOB—vagina—urinary bladder cancer	0.00643	0.0134	CbGeAlD
Methamphetamine—SLC18A2—lymph node—urinary bladder cancer	0.00631	0.0132	CbGeAlD
Methamphetamine—MAOA—female reproductive system—urinary bladder cancer	0.00607	0.0126	CbGeAlD
Methamphetamine—ADRA2A—urethra—urinary bladder cancer	0.00571	0.0119	CbGeAlD
Methamphetamine—SLC22A5—female reproductive system—urinary bladder cancer	0.00559	0.0116	CbGeAlD
Methamphetamine—MAOA—vagina—urinary bladder cancer	0.00549	0.0114	CbGeAlD
Methamphetamine—ADRA2C—vagina—urinary bladder cancer	0.00528	0.011	CbGeAlD
Methamphetamine—SLC22A5—vagina—urinary bladder cancer	0.00505	0.0105	CbGeAlD
Methamphetamine—ADRA2A—female reproductive system—urinary bladder cancer	0.00466	0.0097	CbGeAlD
Methamphetamine—CYP2D6—renal system—urinary bladder cancer	0.0045	0.00939	CbGeAlD
Methamphetamine—SLC22A3—lymph node—urinary bladder cancer	0.0045	0.00937	CbGeAlD
Methamphetamine—ADRA2A—vagina—urinary bladder cancer	0.00421	0.00878	CbGeAlD
Methamphetamine—MAOB—lymph node—urinary bladder cancer	0.00416	0.00867	CbGeAlD
Methamphetamine—SLC6A2—lymph node—urinary bladder cancer	0.00385	0.00803	CbGeAlD
Methamphetamine—CYP2D6—female reproductive system—urinary bladder cancer	0.00361	0.00752	CbGeAlD
Methamphetamine—MAOA—lymph node—urinary bladder cancer	0.00355	0.0074	CbGeAlD
Methamphetamine—ADRA2C—lymph node—urinary bladder cancer	0.00341	0.00711	CbGeAlD
Methamphetamine—Pseudoephedrine—TNF—urinary bladder cancer	0.0033	0.0807	CrCbGaD
Methamphetamine—SLC22A5—lymph node—urinary bladder cancer	0.00327	0.00681	CbGeAlD
Methamphetamine—Nateglinide—PPARG—urinary bladder cancer	0.00324	0.0792	CrCbGaD
Methamphetamine—ADRA2A—lymph node—urinary bladder cancer	0.00272	0.00568	CbGeAlD
Methamphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000211	0.00044	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ERBB2—urinary bladder cancer	0.00021	0.000439	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.00021	0.000439	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GLI1—urinary bladder cancer	0.00021	0.000438	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GPX1—urinary bladder cancer	0.000208	0.000434	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ERCC2—urinary bladder cancer	0.000204	0.000426	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TYMP—urinary bladder cancer	0.000204	0.000426	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—CREBBP—urinary bladder cancer	0.000204	0.000426	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HDAC4—urinary bladder cancer	0.000204	0.000425	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IGF1—urinary bladder cancer	0.000201	0.00042	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000201	0.000419	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTP1—urinary bladder cancer	0.0002	0.000418	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL8—urinary bladder cancer	0.0002	0.000416	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000199	0.000415	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HRAS—urinary bladder cancer	0.000198	0.000414	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—RRM2—urinary bladder cancer	0.000196	0.000409	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—MTHFR—urinary bladder cancer	0.000192	0.000401	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL2—urinary bladder cancer	0.000191	0.000398	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—CREBBP—urinary bladder cancer	0.000191	0.000397	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IGF1—urinary bladder cancer	0.000188	0.000393	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PLAU—urinary bladder cancer	0.000188	0.000391	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000186	0.000389	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TYMS—urinary bladder cancer	0.000186	0.000388	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCND1—urinary bladder cancer	0.000186	0.000388	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NAT2—urinary bladder cancer	0.000185	0.000385	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—RHOA—urinary bladder cancer	0.000185	0.000385	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NCOR1—urinary bladder cancer	0.000184	0.000384	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTM1—urinary bladder cancer	0.000184	0.000384	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—HPGDS—urinary bladder cancer	0.000182	0.000379	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ENO2—urinary bladder cancer	0.000182	0.000379	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000181	0.000378	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000181	0.000377	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MMP9—urinary bladder cancer	0.000181	0.000377	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.00018	0.000377	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CDKN1A—urinary bladder cancer	0.00018	0.000375	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PTEN—urinary bladder cancer	0.000179	0.000374	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NQO1—urinary bladder cancer	0.000178	0.000371	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTT1—urinary bladder cancer	0.000176	0.000367	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GPX1—urinary bladder cancer	0.000176	0.000367	CbGpPWpGaD
Methamphetamine—MAOA—Neuronal System—HRAS—urinary bladder cancer	0.000174	0.000363	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ERCC2—urinary bladder cancer	0.000173	0.000361	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—RHOA—urinary bladder cancer	0.000172	0.00036	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—EP300—urinary bladder cancer	0.000171	0.000357	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000171	0.000356	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GLI1—urinary bladder cancer	0.000171	0.000356	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000169	0.000353	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SRC—urinary bladder cancer	0.000166	0.000347	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000166	0.000347	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MTHFR—urinary bladder cancer	0.000163	0.000339	CbGpPWpGaD
Methamphetamine—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	0.000162	0.000337	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—RRM2—urinary bladder cancer	0.000159	0.000332	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PPARG—urinary bladder cancer	0.000156	0.000325	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IL2—urinary bladder cancer	0.000155	0.000323	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—CREBBP—urinary bladder cancer	0.000155	0.000323	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RBX1—urinary bladder cancer	0.000154	0.000322	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IGF1—urinary bladder cancer	0.000153	0.000319	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CREBBP—urinary bladder cancer	0.00015	0.000312	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MYC—urinary bladder cancer	0.000149	0.000311	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTP1—urinary bladder cancer	0.000148	0.00031	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HPGDS—urinary bladder cancer	0.000148	0.000308	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ENO2—urinary bladder cancer	0.000148	0.000308	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NQO1—urinary bladder cancer	0.000146	0.000305	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—EGFR—urinary bladder cancer	0.000146	0.000304	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TSC1—urinary bladder cancer	0.000145	0.000302	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IL2—urinary bladder cancer	0.000145	0.000302	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RBX1—urinary bladder cancer	0.000144	0.0003	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTT1—urinary bladder cancer	0.000143	0.000298	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—RHOA—urinary bladder cancer	0.00014	0.000292	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—EP300—urinary bladder cancer	0.000139	0.00029	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TYMS—urinary bladder cancer	0.000138	0.000288	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JAG1—urinary bladder cancer	0.000138	0.000288	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—KRAS—urinary bladder cancer	0.000138	0.000287	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000137	0.000287	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NCOR1—urinary bladder cancer	0.000136	0.000285	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTM1—urinary bladder cancer	0.000136	0.000285	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TSC1—urinary bladder cancer	0.000135	0.000282	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SRC—urinary bladder cancer	0.000135	0.000282	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	0.000133	0.000277	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PPARG—urinary bladder cancer	0.000132	0.000275	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GPX1—urinary bladder cancer	0.000131	0.000273	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—EP300—urinary bladder cancer	0.00013	0.000271	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JAG1—urinary bladder cancer	0.000129	0.000269	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ERCC2—urinary bladder cancer	0.000128	0.000268	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CREBBP—urinary bladder cancer	0.000127	0.000264	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SRC—urinary bladder cancer	0.000126	0.000263	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PTGS2—urinary bladder cancer	0.000123	0.000256	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—urinary bladder cancer	0.000122	0.000256	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTP1—urinary bladder cancer	0.000122	0.000255	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—MTHFR—urinary bladder cancer	0.000121	0.000251	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	0.00012	0.000251	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NQO1—urinary bladder cancer	0.000119	0.000248	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL2—urinary bladder cancer	0.000117	0.000245	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HRAS—urinary bladder cancer	0.000117	0.000244	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RBX1—urinary bladder cancer	0.000117	0.000244	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000117	0.000243	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TYMS—urinary bladder cancer	0.000114	0.000237	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NCOR1—urinary bladder cancer	0.000112	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTM1—urinary bladder cancer	0.000112	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—KRAS—urinary bladder cancer	0.000112	0.000233	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—S100B—urinary bladder cancer	0.000112	0.000233	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TSC1—urinary bladder cancer	0.00011	0.000229	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000109	0.000227	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GPX1—urinary bladder cancer	0.000107	0.000224	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PTEN—urinary bladder cancer	0.000107	0.000223	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—RHOA—urinary bladder cancer	0.000106	0.000221	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ERCC2—urinary bladder cancer	0.000105	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—EP300—urinary bladder cancer	0.000105	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JAG1—urinary bladder cancer	0.000105	0.000218	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—KRAS—urinary bladder cancer	0.000104	0.000218	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—S100B—urinary bladder cancer	0.000104	0.000218	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	0.000104	0.000217	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTGS2—urinary bladder cancer	0.000104	0.000216	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SRC—urinary bladder cancer	0.000102	0.000214	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000102	0.000214	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—EP300—urinary bladder cancer	0.000102	0.000213	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NCOR1—urinary bladder cancer	0.0001	0.00021	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—urinary bladder cancer	9.94e-05	0.000207	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTP1—urinary bladder cancer	9.92e-05	0.000207	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTHFR—urinary bladder cancer	9.92e-05	0.000207	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—RHOA—urinary bladder cancer	9.89e-05	0.000206	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL2—urinary bladder cancer	9.78e-05	0.000204	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PPARG—urinary bladder cancer	9.78e-05	0.000204	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.61e-05	0.000201	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.61e-05	0.000201	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.56e-05	0.000199	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—HRAS—urinary bladder cancer	9.51e-05	0.000198	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CREBBP—urinary bladder cancer	9.39e-05	0.000196	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NCOR1—urinary bladder cancer	9.38e-05	0.000196	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.32e-05	0.000195	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—urinary bladder cancer	9.3e-05	0.000194	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—urinary bladder cancer	9.29e-05	0.000194	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TYMS—urinary bladder cancer	9.22e-05	0.000192	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL2—urinary bladder cancer	9.14e-05	0.000191	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NCOR1—urinary bladder cancer	9.11e-05	0.00019	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—urinary bladder cancer	9.11e-05	0.00019	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTEN—urinary bladder cancer	9.04e-05	0.000189	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL2—urinary bladder cancer	8.88e-05	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—HRAS—urinary bladder cancer	8.88e-05	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TERT—urinary bladder cancer	8.85e-05	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	8.85e-05	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GPX1—urinary bladder cancer	8.73e-05	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—urinary bladder cancer	8.68e-05	0.000181	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—EP300—urinary bladder cancer	8.62e-05	0.00018	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	8.57e-05	0.000179	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	8.49e-05	0.000177	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	8.48e-05	0.000177	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—urinary bladder cancer	8.3e-05	0.000173	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TERT—urinary bladder cancer	8.27e-05	0.000172	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGFR3—urinary bladder cancer	8.12e-05	0.000169	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	8.05e-05	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARG—urinary bladder cancer	8.04e-05	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	8.03e-05	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ESR1—urinary bladder cancer	7.89e-05	0.000165	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.77e-05	0.000162	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.75e-05	0.000162	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CREBBP—urinary bladder cancer	7.72e-05	0.000161	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—urinary bladder cancer	7.69e-05	0.00016	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	7.62e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGFR3—urinary bladder cancer	7.59e-05	0.000158	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—urinary bladder cancer	7.54e-05	0.000157	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	7.42e-05	0.000155	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ESR1—urinary bladder cancer	7.37e-05	0.000154	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	7.21e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	7.05e-05	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CREBBP—urinary bladder cancer	6.92e-05	0.000144	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—urinary bladder cancer	6.83e-05	0.000142	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—urinary bladder cancer	6.8e-05	0.000142	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	6.74e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	6.72e-05	0.00014	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTEN—urinary bladder cancer	6.71e-05	0.00014	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARG—urinary bladder cancer	6.53e-05	0.000136	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.46e-05	0.000135	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CREBBP—urinary bladder cancer	6.46e-05	0.000135	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	6.42e-05	0.000134	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—EP300—urinary bladder cancer	6.4e-05	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—urinary bladder cancer	6.38e-05	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—urinary bladder cancer	6.35e-05	0.000132	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—urinary bladder cancer	6.33e-05	0.000132	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	6.27e-05	0.000131	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	6.26e-05	0.000131	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	6.16e-05	0.000129	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.01e-05	0.000125	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	6e-05	0.000125	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	5.99e-05	0.000125	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	5.94e-05	0.000124	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	5.94e-05	0.000124	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	5.84e-05	0.000122	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	5.79e-05	0.000121	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.69e-05	0.000119	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.58e-05	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTEN—urinary bladder cancer	5.52e-05	0.000115	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	5.49e-05	0.000115	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	5.46e-05	0.000114	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	5.41e-05	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—EP300—urinary bladder cancer	5.26e-05	0.00011	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.25e-05	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	5.25e-05	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	5.25e-05	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	5.18e-05	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	5.16e-05	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	5.14e-05	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	5.13e-05	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	5.12e-05	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	5.1e-05	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	4.97e-05	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	4.95e-05	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	4.94e-05	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	4.9e-05	0.000102	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	4.87e-05	0.000102	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	4.78e-05	9.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	4.75e-05	9.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	4.71e-05	9.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	4.64e-05	9.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	4.62e-05	9.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	4.61e-05	9.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	4.58e-05	9.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	4.48e-05	9.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	4.4e-05	9.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	4.39e-05	9.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	4.28e-05	8.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—EP300—urinary bladder cancer	4.27e-05	8.91e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.26e-05	8.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	4.17e-05	8.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	4.14e-05	8.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	4.1e-05	8.56e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.09e-05	8.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	4.01e-05	8.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	3.98e-05	8.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	3.88e-05	8.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	3.83e-05	8e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	3.79e-05	7.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	3.77e-05	7.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.76e-05	7.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	3.75e-05	7.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	3.75e-05	7.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	3.57e-05	7.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	3.54e-05	7.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	3.47e-05	7.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	3.37e-05	7.03e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.35e-05	6.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	3.22e-05	6.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	3.15e-05	6.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	3.11e-05	6.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	3.05e-05	6.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	3.01e-05	6.28e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.92e-05	6.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.88e-05	6e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.78e-05	5.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	2.56e-05	5.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	2.45e-05	5.1e-05	CbGpPWpGaD
